COCP

Company Overview — What Does Cocrystal Pharma, Inc. Do?

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington. Cocrystal Pharma, Inc. (COCP) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Sam Lee and employs approximately 10 people. With a market capitalization of $20M, COCP is one of the notable companies in the Healthcare sector.

Cocrystal Pharma, Inc. (COCP) Stock Rating — Reduce (April 2026)

As of April 2026, Cocrystal Pharma, Inc. receives a Reduce rating with a composite score of 29.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.COCP ranks #2,539 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cocrystal Pharma, Inc. ranks #327 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

COCP Stock Price and 52-Week Range

Cocrystal Pharma, Inc. (COCP) currently trades at $1.21. The stock lost $0.22 (15.4%) in the most recent trading session. Recent trading volume was 595K shares, suggesting relatively thin trading activity.

Is COCP Overvalued or Undervalued? — Valuation Analysis

Cocrystal Pharma, Inc. (COCP) carries a value factor score of 25/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.20x, versus the sector average of 2.75x.

At current multiples, Cocrystal Pharma, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cocrystal Pharma, Inc. Profitability — ROE, Margins, and Quality Score

Cocrystal Pharma, Inc. (COCP) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -179.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -116.8% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

COCP Debt, Balance Sheet, and Financial Health

Cocrystal Pharma, Inc. has a debt-to-equity ratio of 53.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.68x, indicating strong short-term liquidity.

COCP has a beta of 0.67, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Cocrystal Pharma, Inc. is 36/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Cocrystal Pharma, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cocrystal Pharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.78. Net income for the quarter was $-11M. Operating income came in at $-12M.

In FY 2025, Cocrystal Pharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.78. Net income for the quarter was $-9M. Operating income came in at $-9M.

In Q3 2025, Cocrystal Pharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.19. Net income for the quarter was $-2M. Operating income came in at $-2M.

In Q2 2025, Cocrystal Pharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.20. Net income for the quarter was $-2M. Operating income came in at $-2M.

Over the past 8 quarters, Cocrystal Pharma, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing COCP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

COCP Dividend Yield and Income Analysis

Cocrystal Pharma, Inc. (COCP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

COCP Momentum and Technical Analysis Profile

Cocrystal Pharma, Inc. (COCP) has a momentum factor score of 41/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 65/100 reflects moderate short selling activity.

COCP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cocrystal Pharma, Inc. (COCP) ranks #327 out of 838 stocks based on the Blank Capital composite score. This places COCP in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing COCP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full COCP vs S&P 500 (SPY) comparison to assess how Cocrystal Pharma, Inc. stacks up against the broader market across all factor dimensions.

COCP Next Earnings Date

No upcoming earnings date has been announced for Cocrystal Pharma, Inc. (COCP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy COCP? — Investment Thesis Summary

The quantitative profile for Cocrystal Pharma, Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 25/100 indicates premium valuation. High volatility (stability score 36/100) increases portfolio risk.

In summary, Cocrystal Pharma, Inc. (COCP) earns a Reduce rating with a composite score of 29.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on COCP stock.

Related Resources for COCP Investors

Explore more research and tools: COCP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare COCP head-to-head with peers: COCP vs AZN, COCP vs SLGL, COCP vs VMD.